Skip to main content

Table 2 Univariate and multivariate analysis for progression-free survival

From: Pre-treatment metastatic growth rate is associated with clinical outcome in patients with metastatic renal cell carcinoma treated with nivolumab

PFS

Univariate analysis

Multivariate analysis

 

HR

95% CI

p-value

HR

95% CI

p-value

Age (above vs. below median)

1.14

0.52–2.51

0.74

   

sex (male vs. female)

0.57

0.24–1.37

0.21

   

IMDC (poor vs. fav/inter)

2.41

0.88–6.62

0.09

1.57

0.54–4.54

0.41

NLR (above vs. below median)

1.95

0.88–4.33

0.10

   

CRP (above vs. below median)

1.51

0.68–3.351

0.31

   

Line (3rd ≤ vs.2nd)

1.24

0.56–2.74

0.60

   

MGR (2.2 ≥ vs. 2.2 <)

2.98

1.29–6.86

0.01

2.69

1.11–6.49

0.03

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us